OS Therapies receives patent notice of allowance for OST-HER2

OS Therapies (OSTX) announced that it received a notice of allowance from the United States Patent & Trademark Office that a patent will be issued covering the manufacturing methods required for the OST-HER2 commercial product. The USPTO granted a patent term adjustment of 572 days, providing market exclusivity for the OST-HER2 commercial drug product into 2040. OS Therapies is preparing to initiate discussions with the FDA following the successful treatment phase of its Phase 2b clinical trial in the prevention of recurrent, resected, lung metastatic osteosarcoma with a view towards submitting a biologics licensing application and gaining conditional or accelerated FDA approval in 2025. The company recently completed a $7.1M financing in January 2025 and has sufficient capital into mid-2026.